COVID-19：CMIC和Avigan临床试验/制造：III期试验CRO / CDMO
COVID-19：CMIC
为新型冠状病毒感染患者的早期提供做出贡献
中芯国际控股有限公司
在COVID-19患者目标/ III期试验中，我们将为Avigan作为CRO（合同药物开发机构）提供临床试验服务。
此外，作为CDMO（药物制剂开发和制造的合同组织），我们已成为“支持Abigan的生产”。
CMIC集团在其附属公司CMIC CRO中支持临床开发。
此外，CDMIC CMIC CMO将在其主要的国内工厂生产“ Abigan”。
中芯国际集团
https://www.cmicgroup.com/news/20200423
CMIC Supports Avigan Production for Potential COVID-19 Treatment
CMIC Holdings Co., Ltd.
said its affiliate, CMIC Co., Ltd., a contract research organization (CRO) in Japan, is providing monitoring services for Avigan Tablet (favipiravir),
a product that Fujifilm Toyama Chemical Co., Ltd. gained approval in Japan for manufacture and sale as an influenza antiviral drug, phase III clinical trial in Japan
and will support for manufacturing the product as a contract development and manufacturing organization (CDMO).
Also, CMIC CMO Co., Ltd., a CDMO in Japan, will manufacture Avigan Tablet at their main plant to contribute to Fujifilm’s accelerated production schedule.